Human papilloma virus vaccination induces strong human papilloma virus specific cell-mediated immune responses in HIV-infected adolescents and young adults

AIDS. 2015 Mar 27;29(6):739-43. doi: 10.1097/QAD.0000000000000597.

Abstract

The ability of a quadrivalent human papilloma virus (HPV)-16/18/6/11 virus-like particles vaccine (Gardasil) to elicit HPV-specific cell-mediated immune responses was evaluated in antiretroviral therapy (ART)-treated HIV-infected young adults. Results showed that, after three doses of vaccine, central memory and effector memory CD4(+) and CD8(+) T lymphocytes, as well as HPV-specific interleukin (IL)2(+)/CD4(+), interferon-gamma (IFN-γ(+))/CD4(+), IFN-γ(+)/CD8(+) and tumour necrosis factor-alpha (TNF-α)(+)/CD8(+) T lymphocytes and Perforin and Granzyme B secreting CD8(+) T lymphocytes were significantly increased. Notably, results obtained in HIV-infected patients were comparable to those seen in HIV-uninfected age-matched healthy controls.

Publication types

  • Clinical Study
  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Cytokines / metabolism
  • HIV Infections / complications
  • HIV Infections / immunology*
  • Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / administration & dosage*
  • Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / immunology*
  • Human papillomavirus 16
  • Humans
  • Immunity, Cellular / drug effects*
  • Longitudinal Studies
  • Papillomavirus Infections / immunology
  • Papillomavirus Infections / prevention & control*
  • Prospective Studies
  • T-Lymphocyte Subsets / immunology*
  • Vaccination / methods*
  • Young Adult

Substances

  • Cytokines
  • Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18